DNA sequences derived from the genome of the papillomavirus HPV39, their use in in vitro diagnosis and for the production of an immunogenic composition

• US 5,656,423 A
• Filed: 11/16/1993
• Issued: 08/12/1997
• Est. Priority Date: 12/20/1990
• Status: Expired due to Term

• Current Assignee: Roche Molecular Systems Inc (Roche Holding AG)
• Original Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), Institut Pasteur
• Inventors: Streeck, Rolf E., Volpers, Christoph, Orth, Gerard
• Primary Examiner(s): Zitomer, Stephanie W.
• Application Number:
  US08/074,879
• Time in Patent Office: 1,365 Days
• Field of Search: 435/5, 536/23.72, 536/24.32
• US Class Current: 435/5
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 16/084 Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Specific DNA sequences derived from the genome of papillomavirus HPV 39 are provided. Also provided are hybridization probes, and methods for diagnosing genital neoplasias and for detecting infection by HPV 39.

Claims

1. Purified DNA of a HPV39 papillomavirus having the nucleotide sequence shown in FIG. 1 (SEQ ID NO:

9).

2. A fragment of the DNA according to claim 1, wherein said fragment has the nucleotide sequence of the large open reading frame (ORF) of 1.3 kb extending from nucleotide 2050 to nucleotide 776 of FIG. 1 (SEQ ID NO:

9).

3. A fragment of the DNA according to claim 1, wherein the nucleotide sequence of said fragment is the minor ORF extending either from nucleotide 4202 to nucleotide 3875 or from nucleotide 4227 to nucleotide 3875.

4. A fragment of the DNA according to claim 1, wherein said fragment contains at least 15 nucleotides and has the sequence GACA included in the highly conserved glucocorticoid response element (GRE) at nucleotide 6367.

5. A fragment of the DNA according to claim 1, wherein said fragment has a nucleotide sequence selected from the following group of sequences:

Consensus;

GGTACANNNTGTTCT (SEQ ID NO;

     6);

HPV39 (NCR);

TCTACATTTTATACT (SEQ ID NO;

     7); and

HPV39 (L1);

GGGACAGTATGTTCT (SEQ ID NO;

     8).

6. A fragment of the DNA according to claim 1, wherein said fragment has the nucleotide sequence of one of the following genes of HPV39:

E1, E2, E4, E6-E7, L1, L2 and the intergenic non-coding (NC) region.

7. A hybridization probe consisting of the DNA according to any one of claims 1 through 6.

8. A method for the in vitro detection in a biological sample to be tested for an infection due to a papillomavirus of the HPV39 type, said method comprising placing the probe of claim 7 in contact with nucleic acids of a sample under stringent hybridization conditions, detecting a hybrid formed between the viral DNA in the sample and in said probe and, correlating the presence of said hybrid with an infection due to the presence of a papillomavirus of the HPV39 type.

9. A method according to claim 8, wherein said biological sample consists of a genital neoplasia.

10. The method of claim 9 wherein said genital neoplasia is selected from the group consisting of cervical, vulvar, and penile cancers.